Dog Vaccines Market Report 2026

The dog vaccines market size has grown strongly in recent years. It will grow from $3.8 billion in 2025 to $4.07 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rise in dog population globally, increasing awareness of canine diseases, introduction of novel vaccine types, growth of veterinary healthcare infrastructure, rising prevalence of infectious canine diseases.

The dog vaccines market size is expected to see strong growth in the next few years. It will grow to $5.44 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancements in recombinant and dna vaccines, increasing focus on canine preventive healthcare, expansion of veterinary immunization programs, rising investments in canine health r&d, adoption of digital tools for vaccination tracking. Major trends in the forecast period include increasing vaccination awareness among dog owners, development of multivalent vaccines for canines, rising adoption of preventive veterinary care, expansion of pediatric and adult canine vaccine programs, growth in veterinary clinics offering comprehensive immunization services.

The increasing prevalence of zoonotic diseases is expected to drive the growth of the dog vaccines market in the coming years. Zoonotic diseases, also called zoonoses, are infectious diseases that can be naturally transmitted between animals and humans. The incidence of zoonotic diseases is rising due to human population expansion into wildlife habitats, which increases contact with animals and the risk of disease transmission. Dog vaccines play a vital role in preventing the spread of zoonotic diseases from dogs to humans and support broader public health initiatives to control and manage these infections. For example, in February 2023, according to the Council on Foreign Relations (CFR), a US-based independent, nonpartisan think tank and publisher, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases have zoonotic origins. Globally, zoonoses are responsible for 2.7 million human deaths and 2.5 billion disease episodes in people each year. Therefore, the rising prevalence of zoonotic diseases is propelling the growth of the dog vaccines market.

Leading players in the dog vaccines market are concentrating on developing innovative vaccine technologies, such as next-generation recombinant and RNA-based vaccines, to enhance immune response, safety, and duration of protection in companion animals. Next-generation canine vaccines aim to stimulate targeted immunity using advanced platforms, while recombinant vaccines utilize specific antigens to minimize adverse reactions and improve efficacy. For instance, in June 2024, according to Merck & Co. Inc.’s MSD Animal Health, a US-based animal health company, the United States Department of Agriculture (USDA) approved Nobivac NXT Canine Influenza Virus (CIV), a next-generation RNA-particle vaccine for dogs, representing a major advancement in canine influenza prevention by providing rapid immunity onset and enhanced protection against circulating virus strains.

In September 2024, Boehringer Ingelheim, a Germany-based company active in both human and animal health sectors, acquired Saiba Animal Health AG for an undisclosed amount. This acquisition strengthens Boehringer Ingelheim's research and development capabilities in the animal health sector, particularly in innovative therapeutic vaccines for pets, targeting chronic conditions such as allergies, inflammation, and pain. Saiba Animal Health AG, a Switzerland-based company, provides dog vaccines.

Major companies operating in the dog vaccines market are Vetoquinol S.A., Boehringer Ingelheim GmbH, Ceva Sante Animale, Heska Corporation, Merck & Co. Inc., Virbac Animal Health Pvt. Ltd., Elanco Animal Health Incorporated, Zoetis Inc., CZ Vaccines, Indian Immunologicals Ltd., Meiji Holdings Co. Ltd., Bioveta A.S., Phibro Animal Health Corporation, Hester Biosciences Limited, Dechra Pharmaceuticals PLC, Norbrook Inc., Biogenesis Bago SA, Vaxxinova India Private Limited, Bimeda Animal Health Ltd., Lohmann Animal Health GmbH, Biovac Ltd., Zenex Animal Health India Pvt. Ltd., Instituto Rosenbusch S.A.

Asia-Pacific was the largest region in the dog vaccines market in 2025. The regions covered in the dog vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dog vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the dog vaccines market by increasing import costs for raw materials, specialized vaccine formulations, and high-tech delivery systems, particularly impacting North America and Europe, where demand for advanced canine vaccines is high. Attenuated live, recombinant, and DNA vaccines segments are the most affected. However, tariffs are encouraging local manufacturing and innovation in cost-effective vaccine production, supporting regional supply resilience.

The dog vaccines market research report is one of a series of new reports that provides dog vaccines market statistics, including dog vaccines industry global market size, regional shares, competitors with a dog vaccines market share, detailed dog vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the dog vaccines industry. This dog vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dog vaccines constitute a series of administered injections, commencing during the puppy stage and extending into adulthood. These vaccines aim to introduce small amounts of a virus particle to trigger an immune response in the dog's body. This proactive measure enables the dog to mount an immune defense in the event of exposure to bacteria or viruses, thereby preventing illness.

Key categories of dog vaccines encompass attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, and recombinant vaccines. Attenuated live vaccines involve creating a vaccine by reducing the virulence of a pathogen while maintaining its viability. Administration methods include subcutaneous, intramuscular, and intranasal routes, catering to dogs below 6 months and those above 6 months.

The dog vaccines market consists of sales of vaccines for dogs including core dog vaccines, and non-core dog vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.